AZN
AstraZeneca PLC
NYSE · Healthcare · Drug Manufacturers - General · GB
$163.95
−0.88%Oct 19, 2026, 11:00 UTC
ASTRAZENECA PLC announced that it will present more than 100 abstracts, including results from five pivotal Phase III trials and four Presidential Symposium presentations, at the ESMO Congress on October 23–27, 2026.
Source:Oct 15, 2026, 23:15 UTC
ASTRAZENECA PLC shares closed at $166.68, up 2.87% from the previous trading session.
Source:Oct 15, 2026, 23:00 UTC
ASTRAZENECA PLC and Insitro, Inc. signed a multi-year AI drug-discovery partnership focused on potential treatments for MASH and cardiomyopathies.
Source:Oct 15, 2026, 16:15 UTC
The UNIVERSITY OF LIVERPOOL’s Bengaluru campus enrolled nearly 300 undergraduate and postgraduate students in its inaugural cohort across six programmes.
Source:Oct 15, 2026, 10:04 UTC
ASTRAZENECA PLC obtained exclusive global rights to advance certain selected programs under its collaboration with Insitro.
Source:Oct 12, 2026, 23:18 UTC
China’s Center for Drug Evaluation proposed priority review for a new indication of ASTRAZENECA PLC’s rilzabrutinib injection to reduce proteinuria in adults with primary IgA nephropathy.
Source:Oct 11, 2026, 18:45 UTC
ASTRAZENECA PLC committed $1 billion to expand in Massachusetts.
Source:Oct 8, 2026, 10:30 UTC
Kazakhstan's SK-Pharmacy signed a long-term supply contract with ASTRAZENECA PLC.
Source:Oct 8, 2026, 09:15 UTC
Imperial Brands, Inc. shares rose 3.30% to 2,570.00p, leading the FTSE 100 gainers, while other named shares also advanced or declined.
Source:Oct 8, 2026, 08:44 UTC
China's National Medical Products Administration approved ASTRAZENECA PLC and Daiichi Sankyo's Datroway for adults with unresectable or metastatic triple-negative breast cancer who are unsuitable for PD-1/PD-L1 inhibitor treatment.
Source:Oct 8, 2026, 08:30 UTC
ASTRAZENECA PLC reported first-half revenue of $30.7 billion, up 6% at constant exchange rates, and core earnings per share up 11%.
Source:Oct 6, 2026, 23:15 UTC
ASTRAZENECA PLC shares closed at $158.61, up 1.33% from the previous trading day.
Source:Oct 6, 2026, 18:30 UTC
Multiply Labs completed a new funding round led by ASTRAZENECA PLC, LINGOTTO INVESTMENT MANAGEMENT LLP, TERADYNE, INC, and Strange Ventures.
Source:Oct 6, 2026, 12:15 UTC
Multiply Labs raised $75 million in Series B funding led by Dr. Patrick Soon-Shiong and NantWorks, bringing its total funding to more than $100 million.
Oct 6, 2026, 10:15 UTC
AstraZeneca opened a major research and development center in Cambridge, comprising 10 floors of interconnecting workspaces over 570,000 square feet.
Source:Oct 5, 2026, 16:03 UTC
AstraZeneca opened a new global strategic R&D center in Kendall Square, Cambridge, Massachusetts, investing $1 billion and expanding its Massachusetts workforce by more than 50%.
Oct 2, 2026, 06:58 UTC
AstraZeneca and Daiichi Sankyo entered into a clinical collaboration with Summit Therapeutics to test Datroway in combination with ivonescimab across multiple tumour types, including lung and breast cancers.
Oct 2, 2026, 06:30 UTC
Daiichi Sankyo and AstraZeneca agreed to collaborate on clinical trials.
Sep 29, 2026, 23:16 UTC
AstraZeneca (AZN) shares closed at $164.21, down 1.17% from the prior trading session.
Source:Sep 29, 2026, 11:25 UTC
Aquestive Therapeutics, Inc. appointed Richard J. Daly as a director effective October 14, 2026, granting him 57,000 stock options under the company's 2018 Equity Incentive Plan.
Sep 29, 2026, 04:01 UTC
Akeso shares surged as much as 15.65% to HK$106.4 in morning trading after its overseas partner Summit Therapeutics received a US$2 billion strategic investment from AstraZeneca.
Source:Sep 29, 2026, 02:09 UTC
AstraZeneca and Summit Therapeutics announced they will jointly run a series of clinical trials combining ivonescimab with AstraZeneca's cancer therapies, and signed a preliminary agreement to explore ivonescimab combinations with several AstraZeneca antibody-drug conjugates.
Sep 29, 2026, 00:18 UTC
AstraZeneca filed an application with the US Food and Drug Administration for approval of the ORPATHYS-TAGRISSO combination in patients with advanced lung cancer, as disclosed by HUTCHMED.
Sep 28, 2026, 21:48 UTC
AstraZeneca agreed to invest $2 billion in newly issued preferred equity of Summit Therapeutics, convertible into common stock at a 1:1,000 ratio, representing a common stock price of $18.36 per share.
Sep 28, 2026, 21:21 UTC
Eccogene received a $50 million milestone payment from AstraZeneca after initiating a global Phase 3 program for the drug elecoglipron (AZD5004/ECC5004).
Source:Sep 28, 2026, 15:05 UTC
AstraZeneca's oncology sales rose 15% in H1 2026, supported by newer drugs, label expansions and a deep pipeline.
Sep 27, 2026, 10:55 UTC
The European Commission issued an implementing decision on September 25, 2026 formally revoking the EU marketing authorization for Hansoh Pharmaceutical's innovative drug Aumseqa (aumolertinib) as monotherapy.
Source:Sep 25, 2026, 11:00 UTC
The US FDA accepted and granted Priority Review to AstraZeneca's supplemental Biologics License Application for IMFINZI (durvalumab) plus neoadjuvant enfortumab vedotin for patients with muscle-invasive bladder cancer ineligible for or declining cisplatin-based chemotherapy.
Sep 24, 2026, 15:58 UTC
IRLAB Therapeutics AB appointed Jan-Fredrik "Janne" Backman as Chairman of the Board, succeeding Carola Lemne, who stepped down in September 2026.
Source:Sep 14, 2026, 01:56 UTC
AstraZeneca reported that its drug Enhertu (trastuzumab deruxtecan) achieved a median progression-free survival of 14.3 months.
Aug 24, 2026, 12:30 UTC
The FTSE 100 rose 13 points to 10,830 by midday on 24 August 2026, led by miners and travel stocks, while the FTSE 250 slipped 0.1% to 24,703.
Source:Aug 24, 2026, 07:45 UTC
The FTSE 100 index opened flat, easing 0.06% to 10,810, with AstraZeneca falling about 1% and FirstGroup dropping as much as 7% before recovering.
Source:
Page 1Next →